FDA's Oncologic Drugs Advisory Committee will review Zevalin (ibritumomab tiuxetan) on Sept. 11 for treatment of relapsed or refractory low-grade, follicular, CD20+ transformed, B-cell non-Hodgkin's lymphoma and rituximab-refractory follicular NHL. Meeting will begin at 8 a.m. at the Holiday Inn in Bethesda, Md
You may also be interested in...
Idec plans to conduct a Phase IV Zevalin trial to study use of the radioimmunotherapy in patients previously exposed to murine-based anti-cancer therapies, if the product is approved by FDA.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011